|Day Low/High||12.36 / 12.76|
|52 Wk Low/High||11.80 / 19.50|
InTandem3 Data Presented in Oral Symposium at EASD 2017
- Patients on sotagliflozin 200 mg spent 1.3 hours longer in target glucose range per day than placebo
A1C Benefit Sustained over 52 Weeks
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading today, for the September 15th expiration.
First -in-Class Oral Tryptophan Hydroxylase Inhibitor to be Considered for Approval in Europe for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy
Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the August 18th expiration.
Sotagliflozin Demonstrates Statistically Significant Benefit in Primary Endpoint
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2018 expiration.
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Conference Call and Webcast to Follow
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.